Long a lobbying powerhouse in Washington, pharma’s struggling to settle on a strategy for defending itself, according to six industry lobbyists and three company officials who spoke to POLITICO. All ...

Donald Trump, at 78, is aggressively pursuing his second term, marked by significant policy changes and a noticeable physical ...

It’s a Beast of a time in Washington. Donald Trump’s D.C. reality show is full of new characters, plot twists, and ...

Trump proposed a change to Medicare price talks that has long been sought after by the pharmaceutical industry.

The Centers for Medicare & Medicaid Services will begin holding closed-door meetings this week with patients who use the 15 ...

Americans spent $71 billion on weight loss drugs in 2023 - as much as the country spent on foreign aid - Weight loss drugs ...

Independence Health Group, the parent company of Independence Blue Cross, spent $500 million last year to provide ...

Meanwhile, Stat reports that in Ireland — a global pharmaceutical hub — potential U.S. tariffs are raising concerns. Also in the news: Novo Nordisk, PBM legislation in statehouses, same-day ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...

"We are seeing change rapidly with the increasingly high annual maximums being offered in the market and as brokers become ...